​YANTAI/SEOUL, December 27th, 2019 – Yantai Dongcheng Pharmaceutical Group Co., Ltd. (YDP) and DuChemBio Co. Ltd. (DCB) have entered into an Exclusive Development and Licensing Agreement for a diagnostic radiopharmaceutical, [18F]FP-CIT, for the People’s Republic of China and the special administrative regions of HongKong and Macao. The diagnostic radiopharmaceutical will be produced by Nanjing-based Dongcheng-AMS, a wholly owned subsidiary of YDP.

Under this Agreement, YDP will assume responsibility for the development and registration of the proprietary PET/CT – tracer in the assigned Territory. Dongcheng-AMS via its network of GMP-standard radiopharmacies, will also manufacture the tracer and commercialize the finished diagnostic product to Nuclear Medicine departments & Molecular Imaging centers across the country. 
​
The Parties have agreed to closely collaborate in the clinical development and scientific promotion of the [18F]FP-CIT tracer to the Nuclear Medicine and Neurology communities.

Press Release (Korean and Chinese)

Dongkook Lifescience, the leading Korean contrast media supplier has acquired Anseong Supply Center from Bayer Korea.
​
Established in 2017 as a spin-out of Dongkook Pharmaceutical, Dongkook Lifescience is the leading Korean manufacturer and supplier of contrast media for computed tomography (CT) and magnetic resonance imaging (MRI).
​
Dongkook Lifescience has been advised and supported in this acquisition by BGM Associates.

“We are excited to have successfully finalized this transaction with Bayer. The Anseong manufacturing plant and supply center will enable us to significantly expand our fast-growing contrast media business in Korea and internationally. We are extremely grateful to Prof. Maier and his team of BGM Associates who have supported us throughout the entire process and have facilitated the negotiations with Bayer.” - says Mr. Ki-Ho Cheong, CEO of Dongkook Life Science.

Press Release (Korean)

DuChemBio Co., Ltd. (DCB), a leading radio-pharmaceutical company in Korea, and Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, recently announced that they have entered into an exclusive agreement to develop, register and commercialize anti-1-amino-3-18F-fluorocyclo-butane-1-carboxylic acid (FACBC) in Korea.  FACBC is a radiopharmaceutical for positron emission tomography (PET) imaging of recurrent prostate cancer.

FACBC has been granted marketing authorizations by the Food and Drug Administration (FDA) in the US and the European Medicines Agency (EMA) in EU for imaging of men with suspected prostate cancer recurrence. Prostate cancer patients whose blood test for prostate-specific antigen (PSA) indicate that the cancer may have returned after the initial treatment, such as prostatectomy, usually undergo conventional imaging tests (e.g. CT, MRI, bone scintigraphy). However, the chances to find recurrent cancer lesions in such patients using conventional imaging are relatively low. FACBC-enhanced PET imaging is a proven diagnostic tool for highly optimal management of patients with suspected prostate cancer recurrence.

Full press release

Nasdaq Stockholm has today decided to admit the shares of Ascelia Pharma for trading on Nasdaq Stockholm’s Main Market with first day of trading being 13thof March 2019. The additional capital generated from the initial public offering allows Ascelia to fund its global Phase III program for its lead product Mangoral.

Prof. Hans Maier from BGM Associates had joined the company’s board of directors in 2017.

Full Press Release

We are pleased to announce that Prof. Dr. med. Jörg Debatin, MBA has joined the Advisory Board of BGM Associates. Jörg is one of the most well-rounded global health-care leaders with a clear view for the future of medicine. After a most distinguished career as a clinician and researcher in the field of Diagnostic Imaging with tenures at Duke, Stanford, Zürich and Essen, where he served as Chair of the Department of Diagnostic and Interventional Radiology, Jörg opted for a career in Hospital Management. As Medical Director and Chief Executive Officer he oversaw the transformation of the University Medical Center Hamburg-Eppendorf into a showcase of organisational and structural innovation in Germany and beyond.

Jörg subsequently pursued an industrial career as CEO of the blood- and tissue-based diagnostic services provider amedes AG. Until recently he served as the Global Chief Technology and Medical Officer of GE Healthcare.

We very much look forward to working with Jörg in critically important areas such as the digital transformation of healthcare and the future of integrated diagnostics and personalised medicine.

Michael Jung has been instrumental for the foundation of BGM Associates in the spring of 2012. Michael has supported and immensely enriched our early discussions on forming a highly specialised healthcare consulting firm against the backdrop of his profound expertise as a longstanding Director of McKinsey & Company. Michael not only facilitated our first client assignment, but accompanied our strategic discussions and development through all the early years. Now after having established the company, Michael believes we need even more bio-pharma and healthcare expertise on our Advisory Board. With Prof. Dr. med. Jörg Debatin joining the Ad Board, Michael thought this to be the right moment to retire from the Ad Board but of course will stay connected. We owe him a debt of gratitude and wish Michael all the very best for his numerous other engagements and initiatives.

The German Heart Center Berlin performs the entire spectrum of cardiovascular and thoracic operations. It is one of the leading hospitals worldwide for the diagnosis and treatment of cardiovascular diseases.

Full article (in German)

The Fraunhofer MEVIS Institute for Medical Image Computing  Advisory Board has elected Prof. Dr. Hans Maier, BGM Associates, as its Chairman and Mr. Walter Märzendorfer, Siemens Healthineers, as its Vice-Chairman.
 
Fraunhofer MEVIS is a leading developer of medical software solutions for image-supported early detection, diagnosis, and therapy. Embedded in a worldwide network of clinical and academic partners, strong focus is placed on cancer as well as diseases of the circulatory system, brain, breast, liver, and lung. The goal is to detect diseases earlier and more reliably, tailor treatment to each individual, and make therapeutic success more measurable.

Link

During the 2018 annual meeting of the Society of Nuclear Medicine and Molecular Imaging in Philadelphia, representatives of Asan Medical Center, DuChemBio Co., Ltd. and BGM Associates GmbH inked a Licensing Consortium Agreement for the international partnering of the molecular imaging compound – [18F]-fluoroestradiol (FES). [18F]FES is a fluorine-18 labelled radiopharmaceutical used for the imaging of breast cancer patients with positron emission tomography (PET) cameras.
 
Asan Medical Center, one of the leading research hospitals in Asia-Pacific region, has recently finalized its phase III trial in Korea and is now seeking regulatory approval for the [18F]FES from Korean Health Authorities.
 
DuChemBio, the leading radiopharmaceutical company in Korea, alongside BGM Associates are now in charge of the international partnering and development of the breast cancer radiopharmaceutical.